Open | - |
Close | - |
Volume / Avg. | 3.000 / 3.100M |
Day Range | - - - |
52 Wk Range | 1.420 - 13.670 |
Market Cap | $125.288M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NYSE |
RSI | 49 |
Short Interest | 36.45% |
Days to Cover | 7.56 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Emergent BioSolutions (NYSE: EBS) through any online brokerage.
Other companies in Emergent BioSolutions’s space includes: Molecular Partners (NASDAQ:MOLN), Zura Bio (NASDAQ:ZURA), Anixa Biosciences (NASDAQ:ANIX), CytomX Therapeutics (NASDAQ:CTMX) and Galectin Therapeutics (NASDAQ:GALT).
The latest price target for Emergent BioSolutions (NYSE: EBS) was reported by Benchmark on Thursday, March 7, 2024. The analyst firm set a price target for 5.00 expecting EBS to rise to within 12 months (a possible 108.33% upside). 6 analyst firms have reported ratings in the last year.
The stock price for Emergent BioSolutions (NYSE: EBS) is $2.4 last updated March 18, 2024 at 6:26 PM EDT.
There are no upcoming dividends for Emergent BioSolutions.
Emergent BioSolutions’s Q1 earnings are confirmed for Tuesday, May 7, 2024.
There is no upcoming split for Emergent BioSolutions.
Emergent BioSolutions is in the Health Care sector and Biotechnology industry. They are listed on the NYSE.